Swift COronavirus therapeutics REsponse

Resultado final

Crystal structure of free 2019-nCoV Mpro and complex with 13b
Characterization of nCoV standard strain

A prototype strain has been selected and its replication cycle characterized in cell lines suitable for antiviral studies.

Cross-consortium peer-reviewed publication on SCORE's overall achievements

Full overview of SCOREs achievements on the public homepage of the SCORE website wwwscorecoveu

Enzymatic assays for proteases, MTases & RdRp

At least two enzymatic assays are available in HTPS format to screen for inhibitors.

Miniaturized HTPS ExoN assay

A miniaturized HTPS ExoN assay in 96-well and 384-well format will be developed.

Gender equality report

Panel of nCoV of isolates

At least 3 different nCoV isolates will be available for testing the spectrum of activity of inhibitors.

Project website and social media presence
Reverse genetics system

An nCoV full-length cDNA clone is available and this has been used to recover infectious nCoV from (RNA-) transfected mammalian cells.

Publicaciones

COVID-19 and the intensive care unit: vaccines to the rescue

Autores: Kai Dallmeier, Geert Meyfroidt, Johan Neyts
Publicado en: Intensive Care Medicine, Edición 47/7, 2021, Página(s) 786-789, ISSN 0342-4642
Editor: Springer Verlag
DOI: 10.1007/s00134-021-06414-1

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

Autores: Ashleigh Shannon, Barbara Selisko, Nhung-Thi-Tuyet Le, Johanna Huchting, Franck Touret, Géraldine Piorkowski, Véronique Fattorini, François Ferron, Etienne Decroly, Chris Meier, Bruno Coutard, Olve Peersen, Bruno Canard
Publicado en: Nature Communications, Edición 11/1, 2020, ISSN 2041-1723
Editor: Nature Publishing Group
DOI: 10.1038/s41467-020-18463-z

Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds

Autores: Linlin Zhang, McClane Howland, Rolf Hilgenfeld, Marc O. Anderson, Scott Eagon
Publicado en: Bioorganic & Medicinal Chemistry Letters, Edición 41, 2021, Página(s) 127990, ISSN 0960-894X
Editor: Pergamon Press Ltd.
DOI: 10.1016/j.bmcl.2021.127990

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate

Autores: Lorena Sanchez-Felipe, Thomas Vercruysse, Sapna Sharma, Ji Ma, Viktor Lemmens, Dominique Van Looveren, Mahadesh Prasad Arkalagud Javarappa, Robbert Boudewijns, Bert Malengier-Devlies, Laurens Liesenborghs, Suzanne J. F. Kaptein, Carolien De Keyzer, Lindsey Bervoets, Sarah Debaveye, Madina Rasulova, Laura Seldeslachts, Li-Hsin Li, Sander Jansen, Michael Bright Yakass, Babs E. Verstrepen, Kinga P. B
Publicado en: Nature, Edición 590/7845, 2021, Página(s) 320-325, ISSN 0028-0836
Editor: Nature Publishing Group
DOI: 10.1038/s41586-020-3035-9

Drugs against SARS‐CoV ‐2: What do we know about their mode of action?

Autores: Coralie Valle, Baptiste Martin, Franck Touret, Ashleigh Shannon, Bruno Canard, Jean‐Claude Guillemot, Bruno Coutard, Etienne Decroly
Publicado en: Reviews in Medical Virology, 2020, ISSN 1052-9276
Editor: John Wiley & Sons Inc.
DOI: 10.1002/rmv.2143

In vitro activity of itraconazole against SARS‐CoV‐2

Autores: Ellen Van Damme, Sandra De Meyer, Denisa Bojkova, Sandra Ciesek, Jindrich Cinatl, Steven De Jonghe, Dirk Jochmans, Pieter Leyssen, Christophe Buyck, Johan Neyts, Marnix Van Loock
Publicado en: Journal of Medical Virology, Edición 93/7, 2021, Página(s) 4454-4460, ISSN 0146-6615
Editor: John Wiley & Sons Inc.
DOI: 10.1002/jmv.26917

A fluorescence-based high throughput-screening assay for the SARS-CoV RNA synthesis complex

Autores: Cecilia Eydoux, Veronique Fattorini, Ashleigh Shannon, Thi-Tuyet-Nhung Le, Bruno Didier, Bruno Canard, Jean-Claude Guillemot
Publicado en: Journal of Virological Methods, Edición 288, 2021, Página(s) 114013, ISSN 0166-0934
Editor: Elsevier BV
DOI: 10.1016/j.jviromet.2020.114013

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity

Autores: Suzanne J. F. Kaptein, Sofie Jacobs, Lana Langendries, Laura Seldeslachts, Sebastiaan ter Horst, Laurens Liesenborghs, Bart Hens, Valentijn Vergote, Elisabeth Heylen, Karine Barthelemy, Elke Maas, Carolien De Keyzer, Lindsey Bervoets, Jasper Rymenants, Tina Van Buyten, Xin Zhang, Rana Abdelnabi, Juanita Pang, Rachel Williams, Hendrik Jan Thibaut, Kai Dallmeier, Robbert Boudewijns, Jens Wouters, Pa
Publicado en: Proceedings of the National Academy of Sciences, Edición 117/43, 2020, Página(s) 26955-26965, ISSN 0027-8424
Editor: National Academy of Sciences
DOI: 10.1073/pnas.2014441117

A molecular pore spans the double membrane of the coronavirus replication organelle

Autores: Georg Wolff, Ronald W. A. L. Limpens, Jessika C. Zevenhoven-Dobbe, Ulrike Laugks, Shawn Zheng, Anja W. M. de Jong, Roman I. Koning, David A. Agard, Kay Grünewald, Abraham J. Koster, Eric J. Snijder, Montserrat Bárcena
Publicado en: Science, Edición 369/6509, 2020, Página(s) 1395-1398, ISSN 0036-8075
Editor: American Association for the Advancement of Science
DOI: 10.1126/science.abd3629

The nucleotide addition cycle of the SARS-CoV-2 polymerase

Autores: Subhas Chandra Bera, Mona Seifert, Robert N. Kirchdoerfer, Pauline van Nies, Yibulayin Wubulikasimu, Salina Quack, Flávia S. Papini, Jamie J. Arnold, Bruno Canard, Craig E. Cameron, Martin Depken, David Dulin
Publicado en: Cell Reports, 2021, Página(s) 109650, ISSN 2211-1247
Editor: Cell Press
DOI: 10.1016/j.celrep.2021.109650

A prospect on the use of antiviral drugs to control local outbreaks of COVID-19

Autores: Andrea Torneri, Pieter Libin, Joris Vanderlocht, Anne-Mieke Vandamme, Johan Neyts, Niel Hens
Publicado en: BMC Medicine, Edición 18/1, 2020, ISSN 1741-7015
Editor: BioMed Central
DOI: 10.1186/s12916-020-01636-4

Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective

Autores: Mona Seifert, Subhas C Bera, Pauline van Nies, Robert N Kirchdoerfer, Ashleigh Shannon, Thi-Tuyet-Nhung Le, Xiangzhi Meng, Hongjie Xia, James M Wood, Lawrence D Harris, Flavia S Papini, Jamie J Arnold, Steven Almo, Tyler L Grove, Pei-Yong Shi, Yan Xiang, Bruno Canard, Martin Depken, Craig E Cameron, David Dulin
Publicado en: eLife, Edición 10, 2021, ISSN 2050-084X
Editor: eLife Sciences Publications
DOI: 10.7554/elife.70968

Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial

Autores: Laurens Liesenborghs, Isabel Spriet, Dirk Jochmans, Ann Belmans, Iwein Gyselinck, Laure-Anne Teuwen, Sebastiaan ter Horst, Erwin Dreesen, Tatjana Geukens, Matthias M. Engelen, Ewout Landeloos, Vincent Geldhof, Helga Ceunen, Barbara Debaveye, Bert Vandenberk, Lorenz Van der Linden, Sofie Jacobs, Lana Langendries, Robbert Boudewijns, Thuc Nguyen Dan Do, Winston Chiu, Xinyu Wang, Xin Zhang, Birgit We
Publicado en: EBioMedicine, Edición 66, 2021, Página(s) 103288, ISSN 2352-3964
Editor: Elsevier BV
DOI: 10.1016/j.ebiom.2021.103288

SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging

Autores: Wioletta Rut, Katarzyna Groborz, Linlin Zhang, Xinyuanyuan Sun, Mikolaj Zmudzinski, Bartlomiej Pawlik, Xinyu Wang, Dirk Jochmans, Johan Neyts, Wojciech Młynarski, Rolf Hilgenfeld, Marcin Drag
Publicado en: Nature Chemical Biology, Edición 17/2, 2021, Página(s) 222-228, ISSN 1552-4450
Editor: Nature Publishing Group
DOI: 10.1038/s41589-020-00689-z

The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2

Autores: Natacha S. Ogando, Jessika C. Zevenhoven-Dobbe, Yvonne van der Meer, Peter J. Bredenbeek, Clara C. Posthuma, Eric J. Snijder
Publicado en: Journal of Virology, 2020, ISSN 0022-538X
Editor: American Society for Microbiology
DOI: 10.1128/jvi.01246-20

STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters

Autores: Robbert Boudewijns, Hendrik Jan Thibaut, Suzanne J. F. Kaptein, Rong Li, Valentijn Vergote, Laura Seldeslachts, Johan Van Weyenbergh, Carolien De Keyzer, Lindsey Bervoets, Sapna Sharma, Laurens Liesenborghs, Ji Ma, Sander Jansen, Dominique Van Looveren, Thomas Vercruysse, Xinyu Wang, Dirk Jochmans, Erik Martens, Kenny Roose, Dorien De Vlieger, Bert Schepens, Tina Van Buyten, Sofie Jacobs, Yanan Li
Publicado en: Nature Communications, Edición 11/1, 2020, ISSN 2041-1723
Editor: Nature Publishing Group
DOI: 10.1038/s41467-020-19684-y

Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters

Autores: Rana Abdelnabi, Robbert Boudewijns, Caroline S. Foo, Laura Seldeslachts, Lorena Sanchez-Felipe, Xin Zhang, Leen Delang, Piet Maes, Suzanne J.F. Kaptein, Birgit Weynand, Greetje Vande Velde, Johan Neyts, Kai Dallmeier
Publicado en: EBioMedicine, Edición 68, 2021, Página(s) 103403, ISSN 2352-3964
Editor: Elsevier BV
DOI: 10.1016/j.ebiom.2021.103403

Medical treatment options for COVID-19

Autores: Leen Delang, Johan Neyts
Publicado en: European Heart Journal: Acute Cardiovascular Care, Edición 9/3, 2020, Página(s) 209-214, ISSN 2048-8726
Editor: SAGE Publications Ltd
DOI: 10.1177/2048872620922790

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

Autores: Rana Abdelnabi, Caroline S. Foo, Suzanne J.F. Kaptein, Xin Zhang, Thuc Nguyen Dan Do, Lana Langendries, Laura Vangeel, Judith Breuer, Juanita Pang, Rachel Williams, Valentijn Vergote, Elisabeth Heylen, Pieter Leyssen, Kai Dallmeier, Lotte Coelmont, Arnab K. Chatterjee, Raf Mols, Patrick Augustijns, Steven De Jonghe, Dirk Jochmans, Birgit Weynand, Johan Neyts
Publicado en: EBioMedicine, Edición 72, 2021, Página(s) 103595, ISSN 2352-3964
Editor: Elsevier BV
DOI: 10.1016/j.ebiom.2021.103595

Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model

Autores: Rana Abdelnabi, Caroline S Foo, Steven De Jonghe, Piet Maes, Birgit Weynand, Johan Neyts
Publicado en: The Journal of Infectious Diseases, Edición 224/5, 2021, Página(s) 749-753, ISSN 0022-1899
Editor: University of Chicago Press
DOI: 10.1093/infdis/jiab361

Derechos de propiedad intelectual

ANTIVIRAL SUBSTANCES WITH A WIDE SPECTRUM OF ACTIVITY

Número de solicitud/publicación: 20 21100129
Fecha: 2021-02-09

Resultado final

Publicaciones

Derechos de propiedad intelectual

Compartir esta página

Descargar